Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)

Spondyloarthritis Clinical Trial

Official title:

Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00328068
• Other study ID #: ASAS-class-crit-1
• Status: Recruiting
• Phase: N/A
• First received: May 18, 2006
• Last updated: February 12, 2013
• Start date: July 2006
• Est. completion date: June 2013

Study information

• Verified date: February 2013
• Source: Charite University, Berlin, Germany
• Contact: Martin Rudwaleit, MD
• Phone: +49(0)30-8445
• Email: martin.rudwaleit[@]charite.de
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Observational

Clinical Trial Summary

Background:

Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not been fully defined yet. Even less is known about sacroiliac (SI) changes in SpA patients with peripheral symptoms. A pilot study using data from 'paper patients' led to new candidate criteria for early spondyloarthritis. Subsequently, the members of the ASAS International Working Group decided to conduct a prospective multi-centre study to evaluate (validate) the new candidate criteria, and to assess their performance as diagnostic criteria.

Aims of the study:

1. To evaluate the new candidate criteria for axial SpA in a multi-centre setting.

2. To assess the potential role of the new candidate criteria to be used as diagnostic criteria. To accomplish this, inclusion of consecutive and undiagnosed patients is mandatory as are longer periods of follow-up .

3. To compare criteria encompassing the whole group of SpA such as ESSG and Amor criteria against criteria which are tailored to either predominant axial disease or predominant peripheral disease. To accomplish this, both patients with predominant axial disease (back pain) but also patient with predominant peripheral disease (arthritis/enthesitis) will be included.

Description:

Background:

Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not been fully defined yet. Even less is known about sacroiliac (SI) changes in SpA patients with peripheral symptoms. A pilot study using data from 'paper patients' led to new candidate criteria for early spondyloarthritis. Subsequently, the members of the ASAS International Working Group decided to conduct a prospective multi-centre study to evaluate (validate) the new candidate criteria, and to assess their performance as diagnostic criteria.

Aims of the study:

1. To evaluate the new candidate criteria for axial SpA in a multi-centre setting.

2. To assess the potential role of the new candidate criteria to be used as diagnostic criteria. To accomplish this, inclusion of consecutive and undiagnosed patients is mandatory as are longer periods of follow-up .

3. To compare criteria encompassing the whole group of SpA such as ESSG and Amor criteria against criteria which are tailored to either predominant axial disease or predominant peripheral disease. To accomplish this, both patients with predominant axial disease (back pain) but also patient with predominant peripheral disease (arthritis/enthesitis) will be included.

Participating centres:

All ASAS members working in clinical practice are invited to participate in the study. More than one ASAS member/ rheumatologist per centre may participate.

Inclusion criteria:

Include newly referred patients if

• onset of symptoms (back pain / arthritis / enthesitis) < 45 years and

• undiagnosed* disease with the following symptoms:

• chronic back pain (duration of back pain more than 3 months)

• or / and peripheral arthritis (asymmetric arthritis / predominantly of the lower limbs)

• or / and enthesitis

• or / and dactylitis

• Definition of 'undiagnosed':

The patient is being referred to your department because of chronic back pain, arthritis, enthesitis or dactylitis but has not been diagnosed confidently before by the referring physician/rheumatologist as having SpA or as definitely not having SpA. If the referring physician/GP/rheumatologist suspects SpA but is not certain about it, the patient is considered as undiagnosed.

Endpoints of the study:

• Primary endpoint: the diagnosis made by the rheumatologist (ASAS member) after the diagnostic work-up. This expert diagnosis serves as preliminary gold standard against which the various criteria will be compared. Final gold standard will be the outcome (diagnosis) after long-term follow up.

• Secondary endpoints: the diagnosis made by the rheumatologist at 2 and 5 years, respectively, after the first assessment. Thus, all patients should be invited to follow-up visits after 2 and 5 years, respectively.

Further study rules:

• Include all newly referred patients strictly consecutively as long as they meet the inclusion criteria.

• The decision to include a patient should be based solely on the fulfilment of the inclusion criteria, and should be made ideally before you make the final diagnosis (prospective study design).

• Patients who have been diagnosed confidently and correctly by the referring physician prior to being referred to your department cannot be included in the study.

• If you are unable to perform MRIs in your clinical setting you cannot include patients with undiagnosed chronic back pain.

• If you want to include patients with undiagnosed chronic back pain, perform MRI of sacroiliac (SI) joints in the first 10 patients with axial SpA and in the first 10 patients with non-SpA related (mechanical) back pain. In subsequent patients you may perform MRIs as needed on clinical grounds. (Explanation: a minimum number of MRIs in both SpA and non-SpA patients from several centres is necessary to obtain reliable results on sensitivity and specificity of MRI in early axial SpA.)

• MRI of SI joints in patients with peripheral symptoms only will be performed in selected centres (centres already indicated whether this will be possible).

• MRI results will be taken as provided by the local centre (either read by the radiologist or rheumatologist, whoever has greater experience). Results will be categorized into 'presence or absence of active inflammatory lesions compatible with SpA', and 'presence or absence of chronic lesions compatible with sacroiliitis/spondylitis'. (Selected centres will be invited to send us their MRIs for validation of locally performed readings (the intention is to increase the quality of data).

• Plain radiographs of the SI joints and lumbar spine are mandatory in all patients with undiagnosed chronic back pain. Previously taken radiographs are acceptable if they are not older than 6 months. Results are taken as provided locally either by the radiologist or rheumatologist, whoever has greater experience.

• At the end of the diagnostic work up, a preliminary diagnosis must be made by the ASAS rheumatologist as is done in usual daily clinics. It is not important to be absolutely confident about the diagnosis at this stage since this i) reflects daily practice, and ii) the level of confidence with the diagnosis will be assessed as well. (It is more important to include all patients consecutively in your centre in order to avoid any selection bias.) The senior ASAS member should supervise other physicians experienced in SpA in her/his department who participate in the study.

• Patients with peripheral symptoms should be included if they meet the inclusion criteria. Patients with peripheral symptoms and a history of chronic back pain or with concomitant chronic back pain must undergo radiographic examination of the SI joints. Patients with non-specific musculoskeletal pain or arthralgia (without arthritis) only cannot be included.

Data documentation:

The results of the clinical history, physical examination, blood tests, radiographs, and MRIs, and the diagnosis will be entered into the CRF locally by the ASAS member during/after the diagnostic work-up. The diagnosis will be made by the local rheumatologist (ASAS member or an experienced colleague at the centre). The completed CRF should be sent to the coordinating centre (Berlin) for data check and data entry. A copy of the CRF should remain locally at the study centre. The name, date of birth, address, and telephone number must also be kept locally in the centre since follow-up assessments after 2 years and after 5 years are planned.

Sample size and inclusion period:

It is estimated that about 400-500 patients with SpA (ca 250-300 axial and 150-200 peripheral SpA) with complete data sets are needed to allow for a reliable comparison of new candidate criteria with established criteria. Since the prevalence of SpA among newly referred patients with unclear diagnoses varies from centre to centre any calculation of the control group size (and thus total sample size) is bound to be inaccurate. Therefore, the proposal is that each centre recruits as many consecutive patients as possible until indicated by the study coordinators to stop inclusion. The study coordinators can adequately terminate the inclusion period only if the completed CRFs are sent within a reasonably short period of time (< 2 weeks) to the coordinating centre. Data entry and data analysis will be done at the coordinating centre.

DNA/RNA-analysis and biomarker analysis:

In addition to the clinical study which aims to arrive at new classification and diagnostic criteria, two groups of researches will perform laboratory experiments in patients from selected centres: Genetic polymorphisms and gene products (RNA) which are potentially associated with spondyloarthritis will be analysed by Prof. Matthew Brown in Brisbane, Australia. A second group of researchers (Prof. Walter Maksymowych, Canada, Prof. Mikkel Ostergaard, Denmark, Prof. Rob Inman, US, and Prof. David Yu, US) will analyse several biomarkers such as cartilage break-down or bone formation proteins in serum and/or plasma. Data from both experimental projects may be of potential diagnostic value in the future and/or may reveal novel insights into pathophysiological mechanisms of spondyloarthritis.

Longterm follow-up:

A second follow-up visit of all patients 2 years after the first encounter and also 5 years after the first encounter is highly warranted since diagnoses may change over time and the final diagnosis after long-term follow up is the most important gold standard. Thus, a record containing the names, addresses, and phone numbers of all patients included in the study must be stored locally at the study site. The patient is best informed at the first visit that a follow-up assessments 2 and 5 years later are envisaged.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 992
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Include newly referred patients if:

• Onset of symptoms (back pain/arthritis/enthesitis) < 45 years

• Undiagnosed disease with the following symptoms:

• chronic back pain (duration of back pain more than 3 months)

• and/or peripheral arthritis (asymmetric arthritis/predominantly of the lower limbs)

• and/or enthesitis

• and/or dactylitis

Exclusion Criteria:

• No symptoms such as specified in inclusion criteria: back pain, arthritis, enthesitis

• Definite diagnosis

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Spondylarthritis
• Spondylarthropathies
• Spondylarthropathy
• Spondylitis
• Spondylitis, Ankylosing
• Spondyloarthritis

Locations

Country	Name	City	State
Belgium	University Hospital Gent	Gent
Brazil	Rheumatology Division	Sao Paulo
Canada	University of Alberta	Edmonton	Alberta
Canada	The Toronto Hospital	Toronto	Ontario
China	Chinese PLA General Hospital	Beijing
China	Third Affiliated Hospital of Sun Yat-sen University	Guangzhou
Colombia	Division of Rheumatology	Bogota
Denmark	Hvidovre Hospital, University of Copenhagen	Hvidovre
France	Service de Rheumatologie	Marseille
France	Rheumatology B Department	Paris
Germany	Brandt	Berlin
Germany	Universitaetsmedizin Berlin, Charité Campus Benjamin-Franklin, Med. Clinic I, Rheumatology, Hindenburgdamm 30	Berlin
Germany	Rheumazentrum Ruhrgebiet	Herne
Hungary	Géher	Budapest
Indonesia	Seroja Rheumatic Centre	Semarang
Ireland	St. Vincent's Hospital	Dublin
Italy	University of Florence	Firenze
Italy	Arcispedale S. Maria Nouva	Reggio Emilia
Italy	Caterina Naclerio	Scafati (SA)
Mexico	Hospital General de México	Mexico City
Netherlands	VU University Medical Center	Amsterdam
Netherlands	Kennemer Gasthuis, Locatie Deo	HG IJmuiden
Netherlands	University Hospital Maastricht	Maastricht
Spain	Hospital Universitario "Reina Sofia"	Córdoba
Spain	Hospital Universitario Gregorio Marañón	Madrid
Switzerland	Balgrist University Hospital	Zürich
Taiwan	Veterans General Hospital Taipei	Beitou Dist. Taipei
Taiwan	Wei	Taichung City
Turkey	Duruöz	Bornova
Turkey	Division of Rheumatology	Elazig
Turkey	Izmir University Hospital	Izmir
United Kingdom	Glasgow Royal Infirmary, Queen Elizabeth Building	Glasgow
United Kingdom	King George Hospital	Goodmayes
United Kingdom	ChapelChapel Allerton Hospital	Leeds
United States	Case Western Reserve University at MetroHealth Medical Centre	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Countries where clinical trial is conducted

United States,  Belgium,  Brazil,  Canada,  China,  Colombia,  Denmark,  France,  Germany,  Hungary,  Indonesia,  Ireland,  Italy,  Mexico,  Netherlands,  Spain,  Switzerland,  Taiwan,  Turkey,  United Kingdom, 

References & Publications (2)

Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006 Feb;54(2):569-78. — View Citation

Rudwaleit M, Sieper J. Positive and negative predictive values from published studies can be misleading for decision-making in clinical practice. Rheumatology (Oxford). 2006 Jun;45(6):779-80; author reply 780-1. Epub 2006 Apr 4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnosis of Spondyloarthritis		2 years	No
Secondary	Patients with a retained diagnosis of spondyloarthritis after follow-up		2-5 years	No

External Links

•   ASAS is an international society of experts in the field of spondyloarthritis.